NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Solar Urticaria

; .

Author Information

Last Update: April 11, 2019.


Solar urticaria is a chronic acquired photosensitivity disorder. It consists of recurrent episodes of urticaria rash developed on areas of the skin that are exposed to sunlight. Despite being usually a benign condition, it may be extremely disabling, thus limiting everyday activities and severely altering the quality of life of patients.[1][2][3][4]


Exposure of skin to sunlight causes sSolar urticaria. The radiation spectrum of action for solar urticaria ranges from ultraviolet B to visible light (wavelength of 300 nanometers to 500 nanometers) and is variable from one patient to another.[5]


Solar urticaria is an uncommon type of urticaria. It accounts for less than 0.5% of all urticaria cases and 7% of all photodermatoses. The disease usually begins in young adulthood (median age 35 years), but cases of onset in neonates or elderly persons have been reported. There is a female predominance but no ethnicity difference. In the largest series of patients, a history of atopy is noticed in less than 30% of cases. The association of solar urticaria with other types of chronic urticaria may be seen in up to 16% of patients.[6][7]


Solar urticaria pathophysiology is not entirely understood. It is an immediate hypersensitivity reaction, which might be IgE-mediated, occurring after exposure to the sun. The radiation may activate an endogenous substance called chromophore which could be present in the serum and/or the dermis, turning it into an immunologically active photo allergen. This later induces the degranulation of mast cells, resulting in lesions of urticaria. The intradermal positive reaction after injection of patient’s irradiated serum is consistent with the hypothesis of a circulating chromophore.

Certain radiation wavelengths (usually long ones) may inhibit the immunological reaction induced by other wavelengths (usually short ones). This is called the double spectrum of action.

Occasionally, solar urticaria is triggered by an exogenous substance, such as some medications such as atorvastatin, chlorpromazine, tetracycline, or oral contraceptives.[8][9][10]

History and Physical

Erythema and edematous papules occur, within a few minutes after exposure to sunlight, on sun-exposed areas, and even on areas covered with thin and white clothing that allows the solar radiation to reach the underlying skin. Usually, covered skin reacts more severely to the sun when it is exposed. The face and hand skin seems more tolerant to sun radiation. The rash is associated with a sensation of itching or burning. Periorbital and/or mucosal angioedema may also be observed. Dermographism may be noticed in some patients. Systemic symptoms such as nausea, wheezing, dyspnea, or syncope are not uncommon, especially if large areas of the skin are exposed to sunlight during a long period. However, even if systemic symptoms are present, anaphylactic shock rarely occurs in solar urticaria. The cutaneous symptoms resolve in 75% of cases within an hour following the interruption of sun exposure and more within 24 hours. The severity and the duration of the symptoms are also related to the intensity of light.


The diagnosis of solar urticaria is suspected on anamnesis (transient urticarial lesions occurring a few minutes after exposure to sunlight), while the physical examination is normal in the absence of sun exposure.

Symptoms and distribution of solar urticaria can mimic other acquired photodermatoses. Differential diagnosis includes polymorphous light eruption, lupus erythematosus, drug-induced photosensitivity, and photo contact dermatitis. However, solar urticaria may be associated with other photodermatoses, such as polymorphous light eruption and porphyria cutanea tarda.

The diagnosis of solar urticaria is confirmed by photo testing using UVA, UVB, and visible light sources. Sometimes natural light is also used. The aim of photo testing is to determine the spectrum of action (the triggering wavelengths) and the minimal urticarial dose (the minimal dose inducing an urticarial reaction). Determining the spectrum of action is also important for subsequent management so that the patients take precaution to avoid the triggering wavelengths.

The light sources are placed 10 centimeters to 15 centimeters from the back of the patient, and different doses of radiations are delivered. Clinical response is assessed every 10 minutes for an hour. Erythema and wheal occur immediately after photo testing and fade a few minutes after radiation cessation. However, in many cases, photo testing with artificial light sources is not contributive, as it may fail to induce cutaneous lesions, which may be triggered only by natural sunlight exposure. In some cases, repeating photo testing may help to obtain positive results.

A histopathological examination may be performed to rule out other photodermatoses. In solar urticaria, it shows typical features of urticaria which are endothelial swelling and dermal neutrophil, monocyte, and eosinophil infiltration.

Photopatch testing may be beneficial to rule out a drug-induced photosensitivity or a photo contact dermatitis.

Treatment / Management

There are no guidelines for the treatment of solar urticaria. Different treatments have been used with variable success. Sun exposure avoidance is logically recommended, as well as the use of broad-spectrum sunscreens and dark clothing photoprotection.[11][12][13]

By analogy with idiopathic chronic urticaria treatment, antihistamine one receptor agents are largely used. They may induce a relief in most cases but usually at higher doses, two to four times higher than the conventional ones. Antihistamine 1 receptor agents seem to have greater efficacy in delayed onset urticaria, but no effect on the erythema in solar urticaria.

Since chronically exposed areas seem relatively tolerant to sun radiations, phototherapy (UVA, UVB, visible light), and photochemotherapy (PUVA) have been used to induce tolerance (hardening) to sunlight. This hardening process should be based on the spectrum of action and the minimal urticarial dose. PUVA seems to give a longer-lived response than phototherapy alone.

Intravenous immunoglobulins, plasma exchange, cyclosporine, afamelanotide, and omalizumab have been used in patients with refractory solar urticaria with some success.

Oral steroids, leukotriene receptor antagonists, antimalarial drugs, prostaglandin inhibitors, and oral beta-carotene, have shown little or no effect in the management of solar urticaria. Combination therapies are frequently needed to achieve and maintain acceptable clinical relief.

Pearls and Other Issues

Solar urticaria often has a chronic course. Approximately the half of patients continue to be symptomatic ten to 15 years after the disease onset. A longer duration of solar urticaria before the first medical evaluation, as well as an age older than 40 years, are associated with a longer disease course. Patients with exclusive reactivity to visible or natural light seem to have the best prognosis.

Enhancing Healthcare Team Outcomes

Solar urticaria is a enigmatic disorder which is not well understood. while the diagnosis is simple, its management is difficult. The condition is often encountered by the primary care provider, nurse practitioner, dermatologist and internist. However, because the condition can be difficult to distinguish from other itching disorders a referral to a dermatologist is recommended.

There are no guidelines for the treatment of solar urticaria. Different treatments have been used with variable success. Sun exposure avoidance is logically recommended, as well as the use of broad-spectrum sunscreens and dark clothing photoprotection.

Those who fail conservative treatment may be managed with photoherapy and biological agents. Overall, the prognosis for patients with severe urticaria is poor. Many patients are restricted indoors and lead a poor quality of life.[14] (Level V)


To access free multiple choice questions on this topic, click here.

Solar uricaria of the hand and forearm


Solar uricaria of the hand and forearm. Contributed by Talel Badri


Milanesi N, Gola M, Francalanci S. Evaluation of nine patients with solar urticaria during summer. G Ital Dermatol Venereol. 2019 Mar 29; [PubMed: 30924623]
Snast I, Lapidoth M, Uvaidov V, Enk CD, Mazor S, Hodak E, Levi A. Real-life experience in the treatment of solar urticaria: retrospective cohort study. Clin. Exp. Dermatol. 2019 Jul;44(5):e164-e170. [PubMed: 30828851]
Photiou L, Foley P, Ross G. Solar urticaria - An Australian case series of 83 patients. Australas. J. Dermatol. 2019 May;60(2):110-117. [PubMed: 30585308]
Lyons AB, Peacock A, Zubair R, Hamzavi IH, Lim HW. Successful treatment of solar urticaria with UVA1 hardening in three patients. Photodermatol Photoimmunol Photomed. 2019 May;35(3):193-195. [PubMed: 30576021]
Snyder M, Turrentine JE, Cruz PD. Photocontact Dermatitis and Its Clinical Mimics: an Overview for the Allergist. Clin Rev Allergy Immunol. 2019 Feb;56(1):32-40. [PubMed: 29951786]
Fityan A, McGibbon D, Fassihi H, Sarkany RS. Paediatric solar urticaria: a case series. Br. J. Dermatol. 2018 Jun;178(6):1453-1454. [PubMed: 29315482]
Raigosa M, Toro Y, Sánchez J. [Solar urticaria. Case report and literature review]. Rev Alerg Mex. 2017 Jul-Sep;64(3):371-375. [PubMed: 29046033]
Griffin LL, Haylett AK, Rhodes LE. Evaluating patient responses to omalizumab in solar urticaria. Photodermatol Photoimmunol Photomed. 2019 Jan;35(1):57-65. [PubMed: 30338865]
Chicharro P, Rodríguez-Jiménez P, Capusan TM, Herrero-Moyano M, de Argila D. Induction of Light Tolerance Using Narrowband UV-B in Solar Urticaria. Actas Dermosifiliogr. 2018 Dec;109(10):888-892. [PubMed: 30205902]
Farr PM. Erythropoietic protoporphyria and solar urticaria. Br. J. Dermatol. 2018 Aug;179(2):542. [PubMed: 29683481]
Maurer M, Fluhr JW, Khan DA. How to Approach Chronic Inducible Urticaria. J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1119-1130. [PubMed: 30033913]
Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, Confino-Cohen R, Hodak E, Levi A. Omalizumab for the Treatment of Solar Urticaria: Case Series and Systematic Review of the Literature. J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1198-1204.e3. [PubMed: 29572192]
Morgado-Carrasco D, Fustà-Novell X, Podlipnik S, Combalia A, Aguilera P. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature. Photodermatol Photoimmunol Photomed. 2018 May;34(3):194-199. [PubMed: 29171925]
Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: Assessment of action spectra and impact on quality of life in adults and children. Photodermatol Photoimmunol Photomed. 2018 Jul;34(4):262-268. [PubMed: 29533487]
Copyright © 2020, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK441986PMID: 28723015


  • PubReader
  • Print View
  • Cite this Page

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...